Clinical Trial Update: Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of an oral PI3K/mTOR inhibitor in patients with advanced refractory solid tumors has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Oral PI3K/mTOR inhibitor

Snippet

Sponsor: Piramal Enterprises Limited | Conditions: Advanced Refractory Solid Tumors | Phase 1 | Status: SUSPENDED